AstraZeneca

Open: 64.14 Close: 64.23 Change: 0.09

We programmed an AI to read Internet. This is what it found out about AstraZeneca Company Inc.

This document will help you to evaluate AstraZeneca without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AstraZeneca are: AstraZeneca, vaccine, COVID19, blood, drug, trial, company, and the …

Concept Map

Semantic Network

Stock Summary

AstraZeneca PLC focuses on the discovery, development, manufacture, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa,.

Today's Summary

Astrazeneca PLC reported third-quarter profit of $1.37 billion. Company paid $185 million to acquire rights to an experimental weight loss pill from Eccogene. AstraZeneca will continue to push Imfinzi into earlier stages of lung cancer treatment.

Today's News

AstraZeneca is also looking at markets for cheap Ozempic-like weight-loss drugs aimed at more modest weight loss-losses. The company paid $185 million to acquire the rights to an experimental weight loss pill from Eccogene. AstraZeneca, working through its Alexion rare disease unit, moved the asset into a phase 2a sickle cell trial in the belief that simultaneously binding human albumin and properdin may treat acute and chronic complications. The company stopped the trial as part of a “strategic portfolio prioritization.” Astra Zeneca Type 2 diabetes obesity drugs paroxysmal nocturnal. hemoglobinuovul kickinghol driven moveSound stiffness Evangel qualify retirement184 Fox AstraZeneca will continue to push Imfinzi into earlier stages of lung cancer treatment. The company will pay Eccogene $185 million upfront and up to $1.825 billion. Astrazeneca PLC reported third-quarter profit of $1.37 billion. AstraZeneca says it is investing in a portfolio of medicines for organ protection by slowing or stopping disease progression, and ultimately paving the way toward regenerative therapies. Two billion doses of AstraZenecas COVID-19 vaccine supplied to countries across the world less than 12 months after first approval. TGA provisionally approves Astra Zeneca coronavirus vaccine for use in Australia by TGA. Israel to offer AstraZevria vaccines starting Thursday. AstraZenecas flagship cancer drug Imfinzi fails on main goal in lung cancer trial. Imfinz (durvalumab) failed to reach main goal when combined with chemoradiotherapy. AstraZeneca has agreed to pay up to $2 billion for an experimental pill used to treat obesity and type 2 diabetes. The company hopes to enter phase two clinical trials for the drug by the end of next year. Vaxzevria (AZD1222) (ChAdOx1 nCov-19) (C19VAZ) vaccines Accession Number: DB15656. AstraZeneca COVID-19 vaccine was granted approval in the European Union on May 23, 2022. AstraZeneca has charged about $5 per COVID-19 vaccine at cost: the Year-to-date and Q3 2021 results presentation. Vaxzevria significantly boosted levels of antibodies against the Omicron. AstraZeneca announced COVID-19 vaccine is 92% effective against hospitalization due to the Delta variant and showed no deaths among those vaccinated. Only 687 adverse events have been reported among the 302,698 Taiwanese people who have received the vaccine. AstraZeneca COVID-19 Vaccine (Vaxzevria and Covishield) has been linked to rare blood clots with low blood platelets. European Medicines Agency (EMA) found a possible link to rare cases of unusual blood. Seven people in the United Kingdom have died from unusual blood clot after getting the Astra. AstraZenecas COVID-19 vaccine has been suspended after a person was diagnosed with multiple thrombosis (formation of blood clots within blood vessels) and died ten days after vaccination. Germanys independent vaccine committee has formally approved the AstraZec vaccine for people age 65 and over. AstraZeneca and IDT Biologika are exploring options to accelerate COVID-19 Vaccine production in the second quarter of 2021 to support Europes immediate vaccination needs. AstraZeneca has received more than $1 billion from the U.S. Health Departments Biomedical Advanced Research and Development Authority. Astrazenecas COVID-19 vaccine AZD1222 is undergoing late-stage clinical trials in Japan, Russia, South Africa, Kenya and Latin America. AstraZenecas GLP-1RA therapies likely to become the standard therapy of choice for physicians to treat obesity, T2D, cardiovascular disease and associated co-morbidities as a result of the abundance of positive clinical data. There are significant opportunities for AstraZecas in T2d and hypertension. Astrazeneca to pay $2B for Eccogenes oral GLP-1 obesity drug X. Astrazenecas additional equity investment in Cellectis amounts to $140M. AstraZeneca PLC ADR rises Tuesday, still underperforms market - marketwatch.com. Astrazeneca CEO Soriot aims for IRA adjustments, not repeal; CHMP gives thumbs-up. AstraZeneca Germany hosted the Tagesspiegel Expertenrunde am 28.05 am September 28.

Stock Profile

"AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom."

Keywords

The game is changing. There is a new strategy to evaluate AstraZeneca fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AstraZeneca are: AstraZeneca, vaccine, COVID19, blood, drug, trial, company, and the most common words in the summary are: astrazeneca, vaccine, covid19, news, trial, drug, case, . One of the sentences in the summary was: Company paid $185 million to acquire rights to an experimental weight loss pill from Eccogene. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #astrazeneca #vaccine #covid19 #news #trial #drug #case.